Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1132403

	registered interest
	date	17/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Lumacaftor/ivacaftor
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what contingency plans his Department has put in place in the event that Vertex declines NHS England’s latest offer for the supply of Orkambi.
	tabling member constituency	Birmingham, Selly Oak
	tabling member printed	Steve McCabe
	uin	265417
	answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>NHS England is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi, and Symkevi in advance of assessment by the National Institute for Health and Care Excellence (NICE), and expanded access to Kalydeco which is already funded on the National Health Service for certain patients.</p><p>The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to urge Vertex to accept NHS England’s generous offer, but we will explore other options to ensure patients can access treatments as soon as possible.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 265418 question first answered 20/06/2019 09:33:36 answering member 4455 label Biography information for Seema Kennedy
	tabling member	298 label Biography information for Steve McCabe

1132404

	registered interest
	date	17/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Lumacaftor/ivacaftor: Clinical Trials
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of launching a large scale clinical trial of the generic version of Orkambi.
	tabling member constituency	Birmingham, Selly Oak
	tabling member printed	Steve McCabe
	uin	265418
	answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>NHS England is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi, and Symkevi in advance of assessment by the National Institute for Health and Care Excellence (NICE), and expanded access to Kalydeco which is already funded on the National Health Service for certain patients.</p><p>The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to urge Vertex to accept NHS England’s generous offer, but we will explore other options to ensure patients can access treatments as soon as possible.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 265417 question first answered 20/06/2019 09:33:36 answering member 4455 label Biography information for Seema Kennedy
	tabling member	298 label Biography information for Steve McCabe

1131849

	registered interest
	date	12/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to improve NHS waiting times for cancer patients.
	tabling member constituency	Birmingham, Selly Oak
	tabling member printed	Steve McCabe
	uin	263683
	answer	answer is ministerial correction date of answer 19/06/2019 answer text <p>The NHS Long Term Plan sets out plans to improve early cancer diagnosis, and a new ambition that, by 2028, the proportion of cancers diagnosed at stages one and two will rise from around half to three-quarters of cancer patients. This will be achieved through raising greater awareness of symptoms of cancer, accelerating access to diagnosis and treatment, maximising the number of cancers that are identified through screening, and harnessing new innovations in technology. A radical overhaul of the way diagnostic services are delivered will ensure that people can get their diagnosis more quickly, including the roll-out of new Rapid Diagnostic Centres across the country to upgrade and bring together the latest diagnostic equipment and expertise.</p><p> </p><p>The independent cancer taskforce recommended the introduction of a new faster diagnosis standard to ensure that people receive a life changing confirmation of whether or not they have cancer within 28 days. This proposed new standard is being considered as part of the clinical review of National Health Service access standards currently being undertaken by NHS England.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 19/06/2019 14:26:47 answering member 4455 label Biography information for Seema Kennedy
	tabling member	298 label Biography information for Steve McCabe